← Leaderboards
Autumn Schulze
Mayo Clinic Rochester
$1,152,872
Attributed
$1,942,030
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $431.9K · FY2016–20$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,942,030 · 1
By mechanism
R01$1,942,030 · 1
Top collaborators
- Stephen J Russell6 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Richard G Vile$15,977,609
- Kah-Whye Peng$11,311,466
- David J Dingli$2,457,123
- Scott H Kaufmann$29,002,745
Others in their field
Top investigators on “Extravasation”
- Mikael Knip · University Of Helsinki$16,568,076
- Katerina Akassoglou · University Of California San Diego$14,886,291
- Dorothy J Becker · Children'S Hosp Pittsburgh/Upmc Hlth Sys$13,640,541
- Sarah Y. Yuan · University Of South Florida$13,466,212
- Jian-Xing Ma · University Of North Texas Hlth Sci Ctr$11,994,246
- Donald M McDonald · University Of California San Francisco$9,942,059
Research focus
ExtravasationAnimalsAntibodiesAttenuatedBaseCancer CellCancer TherapyCapsidCapsid ProteinsCardiacCardiotoxicityCell KillingCellsClinical TrialsCombined Modality TherapyCtag1 GeneCytokineDependenceDoseEncephalitisEngineeringEquilibriumExhibitsFamily Picornaviridae
Grant awards (7)
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2020 · CA · contact PI
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$352,802
R01 · FY2019 · CA
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$66,165
R01 · FY2019 · CA
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2018 · CA
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$68,211
R01 · FY2018 · CA
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2017 · CA
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2016 · CA